Therapy-related myelodysplastic syndrome in childhood: a retrospective study of 36 patients in Japan.
We report here a retrospective analysis of 36 children with therapy-related myelodysplastic syndrome (t-MDS) diagnosed between 1990 and 1999 in Japan. Their median age was 7.7 years and the median latency period for the development of t-MDS was 38.5 months. The primary tumors were hematologic in 15 of the cases and nonhematologic in 21. Chromosomal abnormalities were detected in 32/34(94%) patients: abnormalities of chromosomes 5and/or 7 in 41% and notably, 11q23 abnormalities in 31%. The prognosis of children with t-MDS was very poor as compared to children with primary MDS (5 year survival: 16% versus 54%, p<0.0001).
Tsurusawa
M
M
Department of Pediatrics, Faculty of Medicine, Aichi Medical University, Aichi 4801195, Japan. tsuru@aichi-med-u.ac.jp
Manabe
A
A
Hayashi
Y
Y
Akiyama
Y
Y
Kigasawa
H
H
Inada
H
H
Noguchi
Y
Y
Sawai
N
N
Kobayashi
R
R
Nagatoshi
Y
Y
Kawakami
K
K
Kojima
S
S
Nakahata
T
T
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics; D003131:Combined Modality Therapy / Q000009:adverse effects*; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000175:diagnosis / Q000235:genetics; D011379:Prognosis; D012189:Retrospective Studies; D018401:Sample Size; D016019:Survival Analysis; D016896:Treatment Outcome